A phase 1, multicenter, open label, clinical trial of immune response, safety and tolerability of DNA vector pPRA-PSM with synthetic peptides E-PRA and E-PSM [MKC 1106-PP; MannKind Corporation] in subjects with advanced solid malignancies
Phase of Trial: Phase I
Latest Information Update: 02 Aug 2010
At a glance
- Drugs MKC 1106 PP (Primary)
- Indications Solid tumours
- Focus Adverse reactions; Therapeutic Use
- 02 Aug 2010 Actual end date (Nov 2009) added as reported by ClinicalTrials.gov.
- 02 Aug 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 30 Oct 2009 Data were presented at the International Society for Biological Therapy of Cancer 2009 Annual Meeting.